MajorAntifungal, triazole×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
The body clears rivaroxaban by two routes. The liver breaks down about two thirds of the dose through CYP3A4, CYP2J2 and CYP-independent pathways, and the kidneys excrete the remaining third unchanged, mainly by active secretion. Rivaroxaban is a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Itraconazole and its main metabolite, hydroxy-itraconazole, strongly inhibit CYP3A4, and itraconazole also inhibits P-gp and BCRP, so it blocks both elimination routes of rivaroxaban (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; itraconazole label, US Food and Drug Administration, FDA). The pair has not been studied directly. With ketoconazole, another strong CYP3A4 and P-gp inhibitor, mean rivaroxaban exposure rose 2.6-fold and peak concentration 1.7-fold, and the anticoagulant effect increased markedly (rivaroxaban SmPC, EMA). Higher rivaroxaban levels raise the risk of bleeding (rivaroxaban SmPC, EMA).
Symptoms
Bleeding is the main risk. Mucosal bleeding is the most common: nosebleeds, gum bleeding, gastrointestinal and genitourinary bleeding, including heavy or prolonged menstrual bleeding. Anaemia also occurs (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Hidden bleeding may show as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock without an obvious cause, and anaemia can cause chest pain or angina (rivaroxaban SmPC, EMA). Severe bleeding can lead to compartment syndrome and to kidney failure from poor kidney perfusion (rivaroxaban SmPC, EMA).
Management
Avoid the combination. Rivaroxaban is not recommended with systemic azole antifungals, including itraconazole, because they strongly inhibit the enzyme CYP3A4 and the transporter P-glycoprotein (P-gp) and can raise rivaroxaban levels to a clinically relevant degree (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). In the Spanish itraconazole SmPC, rivaroxaban also appears among the combinations that are not recommended: avoid it during itraconazole treatment and for 2 weeks after stopping, unless the benefit outweighs the risk (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US labels give the same advice: avoid rivaroxaban with drugs that inhibit P-gp and strongly inhibit CYP3A, and do not use it with itraconazole during treatment and for 2 weeks after (rivaroxaban and itraconazole labels, US Food and Drug Administration, FDA). The European Heart Rhythm Association (EHRA) marks the pair red, which means contraindicated or not advisable because of higher drug levels (EHRA 2021). The 2-week window exists because itraconazole levels fall to almost undetectable within 7–14 days of the last dose, and even more slowly in liver cirrhosis (itraconazole SmPC, AEMPS). If itraconazole cannot be avoided, monitor the patient closely for bleeding and, if needed, reduce the rivaroxaban dose or stop it (itraconazole SmPC, AEMPS). Haemoglobin and haematocrit help detect hidden bleeding. Look for a bleeding source if haemoglobin or blood pressure drops without explanation, and stop rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA). Take extra care in patients with reduced kidney function who also take other drugs that raise rivaroxaban levels (rivaroxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Sporanox 100 mg cápsulas (itraconazol) (2026)– AEMPS CIMA, Sporanox 100 mg cápsulas, nº registro 59343, secciones 4.3 y 4.5
- FDA: Sporanox (itraconazole) capsules prescribing information (2026)– Janssen Pharmaceuticals. SPORANOX (itraconazole) capsules. Prescribing information, DailyMed setid a4d555fa-787c-40fb-bb7d-b0d4f7318fd0, Contraindications and Drug Interactions table
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6